- Rating
- 1
- Confidence
- 4
- Informativeness
- 1
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
Thia paper proposes a FlowSeed framework to synthesize contrast-enhanced CT from non-contrast CT (NCCT) as NCCT plus a non-negative residual, conditioned on scalar post-injection time. Time modulates the features per organ through a predicted soft organ map, and a “Gaussian-weighted residual splatting” decoder renders the residual slice by slice. It adds an ordinal liver/aorta loss and a PatchGAN. It reports the best aggregate metrics on MCT-LTDiag and the best MAE and SSIM on external WAW-TACE.
Critical strengths
- The paper is well written and easy to follow.
- The residual formulation is sensible. Anatomy is preserved by construction, and time is a more natural conditioning variable than a phase label.
Critical weaknesses
-
The continuous-time claim is not well validated. There is no ground truth exists at intermediate times. There is no ablation of the same architecture with categorical phase or fixed phase-centre times, so gains from continuous time cannot be separated from gains from architecture.
-
Enhancement agreement is weak. Pooled Mean-HU CCC is 0.27–0.32, and within-phase values are far lower (abdominal vessels 0.120/0.063/0.132 against 0.320 pooled). The pooled figure therefore mostly reflects between-phase differences, not patient-specific prediction.
-
Trivial baselines are missing. Parenchymal MAE (42.5 HU) is comparable to liver enhancement itself (about 50 HU in Fig. 3). An identity baseline and an “NCCT + per-organ, per-phase mean enhancement” baseline are needed. Pix2Pix at 163 HU is almost certainly worse than identity, which suggests the baselines were poorly adapted.
-
The proposed FlowSeed is trained with organ-masked losses and gating and evaluated only inside those organs. It also receives recorded time while the baselines receive only phase.
-
The external vessel results need explaination. For example, on WAW-TACE, abdominal-vessel MAE is 162.6 HU with +121 HU bias and CCC 0.058; in the delayed phase, MAE is 232 HU. SSIM is higher than on the internal set, and external parenchymal MAE (30.1) beats internal (42.5).
-
The time labels are questionable. UCSF times are regressed from the HU statistics of the target scans themselves, with a 30s delayed-phase MAE. The regressor’s training data is unspecified, and renal protocols may fall outside its range. More fundamentally, time since injection does not determine enhancement without the injection protocol, bolus tracking and cardiac output.
-
The split of train/test is provided, it is unclear how the loss weights, margin and stopping point were chosen.
Questions for authors
- What are t_A, t_V, t_D in Eq. 11: fixed reference times or per-study recorded times?
- Were segmentation masks derived from NCCT or from the enhanced scans?
- What were the registration QC criteria, and where were the “preregistered” surrogates and “frozen” protocol registered?